In January, Gary Smith left the top spot at skin biopsy device company CleveX to join IR Diagnostyx, a Columbus-based blood diagnostics startup built on technology pioneered at Ohio State University.
Columbus-based skin biopsy device maker CleveX Inc. is seeking a $637,500 loan that it would use to purchase equipment and machinery to boost production capacity for its ExiClip line of devices. Youngstown-based Syncro Medical Innovations is looking for a $490,500 loan to protect intellectual property and acquire equipment and machinery.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
CleveX Inc., a promising start-up that has created a device to make it easier to do skin biopsies, has received the second half of $1.7 million promised late last year by investors during the company’s Series B funding round. Investors wanted to break their commitment into two equal tranches “to make sure the company continued […]
Early stage venture group Ohio TechAngel Funds has raised $2.5 million for its third investment fund. Like the group's previous funds, Ohio TechAngel Fund III will invest in Ohio-based technology companies in the life and physical sciences, and information technology industries.
Biopsy device company CleveX got a slow start to its product launch. But it since hired a new chief executive officer to, in his words, "turbo-charge existing management." Sam Finkelstein discusses the challenges and opportunities of the ExiClip.
Sam Finkelstein said he was in Florida on Monday meeting with clients and other business partners. He is the former chief executive of Riverain Medical, which makes chest imaging devices. He replaces Gary Smith, who will serve as CleveX's president and focus more on sales and marketing of its device, the ExiClip.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.